Clinical Trial Market Research Reports & Industry Analysis

Looking Ahead to 2025 - the Future of Pharma​ Summary This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, an ...

The global locally advanced pancreatic cancer market size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.38 billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033. Locally advanced pancreatic cancer refers to a stage of pancreatic cancer where the tumor is c ...

The Global Contract Research Organization Market was valued at USD 59.8 billion in 2023 and is estimated to grow at a CAGR of 8.1%, reaching USD 118.2 billion by 2032 driven by increasing R&D expenditures across pharmaceutical, biotechnology, and medical device sectors, alongside the rising complexi ...

The AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into di ...

“Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Murine Double Minute 2 (MDM2) Inhibitor development. The report provides detailed coverage of ...

“Anti-Lymphotoxin - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Lymphotoxin development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ...

“Alpha-1 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-1 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism ...

“Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3 Integrin Antagonist development. The report provides detailed coverage of the pipeli ...

“Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3/5/6 Integrin Antagonist development. The report provides detailed coverage of th ...

“Akt1 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Akt1 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of actio ...

Cell And Gene Therapy Clinical Trial Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market. This report focuses on cell and gene therapy clinical trial services market w ...

Key Highlights Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2023, accounting for nearly 70% of the total KRAS Inhibitor market share. Among the approved KRAS Inhibitor therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenu ...

In our latest quarterly review of corporate sustainability impacts, risks and opportunities, we find that biotechnology and pharmaceutical companies have made substantial ESG commitments. This edition also analyses the effects of government tariffs and trade policy uncertainty on sustainable API sou ...

DelveInsight’s, “Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als ...

DelveInsight’s, “Huntington’s Disease - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the t ...

DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the th ...

DelveInsight’s, “Sarcopenia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessmen ...

DelveInsight’s, “Diabetic Nephropathy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ...

DelveInsight’s, “B-cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutic ...

DelveInsight’s, “Potassium channel antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ...

DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, includ ...

“Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Potential Cation Channel, Sub ...

“Sigma Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sigma Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this me ...

“Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Kv1.3 Potassium Channel Blockers development. The report provides detailed coverage of the pipeline l ...

“Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Apolipoprotein B (ApoB) Inhibitor development. The report provides detailed coverage of the pipeline ...